Osteoscreen, Ltd. has just been awarded a patent for their method of stimulating hair growth.
The US Patent #7,223,554 was awarded on May 29, 2007. The patent is titled: Inhibitors of proteasomal activity for stimulating hair growth.
For all intents and purposes Osteoscreen’s technology now belongs to Neosil since Neosil has licensed their hair growth technology and is in the process of conducting hair loss clinical trials.
In connection with this licensing, Neosil appointed OsteoScreen’s founder and Chief Executive Gregory Mundy, M.D. to its Board of Directors.
In the patent Osteoscreen states that: The present invention adds to the repertoire of osteogenic and hair growth stimulating agents by providing drugs which would inhibit key proteins and enzymes involved in proteasomal activity and which decrease the activity of the nuclear transcription factor NF-.kappa.B, and thus stimulate bone or hair growth. In accordance with the present invention, we have discovered that inhibition of the functions of the proteasomal proteins and, to a lesser extent, of NF-.kappa.B in bone cells leads to increased bone growth and to hair follicle formation and stimulation; the effect on hair is also exhibited by inhibitors of NF-.kappa.B. Thus, assessing a candidate compound for its ability to inhibit proteasomal proteins or NF-.kappa.B provides a useful means to identify bone and hair growth anabolic agents.
The present specification thus provides methods for identification of osteogenic compounds to stimulate bone growth and compounds that stimulate hair growth by assessing their capacity to inhibit proteasome activity and to stimulate hair growth by assessing their ability to inhibit the activity of the transcription factor NF-.kappa.B, preferably to inhibit proteasomal activity.
OsteoScreen is a privately held biotechnology company located in San Antonio, Texas which was founded in 1988 as a joint venture with the University of Texas Health Science Center. The company focuses on the identification and clinical development of new drugs for common diseases of bone.
» Osteoscreen, Ltd. has just been awarded a patent for their method of
» stimulating hair growth.
»
» The US Patent #7,223,554 was awarded on May 29, 2007. The patent is
» titled: Inhibitors of proteasomal activity for stimulating hair growth.
»
» For all intents and purposes Osteoscreen’s technology now belongs to
» Neosil since Neosil has licensed their hair growth technology and is in
» the process of conducting hair loss clinical trials.
»
» In connection with this licensing, Neosil appointed OsteoScreen’s founder
» and Chief Executive Gregory Mundy, M.D. to its Board of Directors.
»
» In the patent Osteoscreen states that: The present invention adds to the
» repertoire of osteogenic and hair growth stimulating agents by providing
» drugs which would inhibit key proteins and enzymes involved in proteasomal
» activity and which decrease the activity of the nuclear transcription
» factor NF-.kappa.B, and thus stimulate bone or hair growth. In accordance
» with the present invention, we have discovered that inhibition of the
» functions of the proteasomal proteins and, to a lesser extent, of
» NF-.kappa.B in bone cells leads to increased bone growth and to hair
» follicle formation and stimulation; the effect on hair is also exhibited
» by inhibitors of NF-.kappa.B. Thus, assessing a candidate compound for its
» ability to inhibit proteasomal proteins or NF-.kappa.B provides a useful
» means to identify bone and hair growth anabolic agents.
»
» The present specification thus provides methods for identification of
» osteogenic compounds to stimulate bone growth and compounds that stimulate
» hair growth by assessing their capacity to inhibit proteasome activity and
» to stimulate hair growth by assessing their ability to inhibit the
» activity of the transcription factor NF-.kappa.B, preferably to inhibit
» proteasomal activity.
»
» OsteoScreen is a privately held biotechnology company located in San
» Antonio, Texas which was founded in 1988 as a joint venture with the
» University of Texas Health Science Center. The company focuses on the
» identification and clinical development of new drugs for common diseases
» of bone.
Soooo, does this mean its one step closer to being released??